Certara, Inc. (CERT) AI Stock Analysis

Certara, Inc. is a provider of software products and technology-enabled services specializing in biosimulation across various stages of drug discovery, preclinical and clinical research, regulatory submissions, and market access. The company supports clients throughout the drug development lifecycle, guiding drug candidates through regulatory approvals and commercialization. Its services portfolio includes mechanistic and empirical biosimulation, clinical pharmacology, regulatory writing, and market access strategies. Certara's software portfolio comprises specialized platforms such as mechanistic biosimulation, PK/PD biosimulation, scientific informatics, and regulatory submission management, serving biopharmaceutical companies, academic institutions, and government entities globally.

Certara increased revenue from $286.1M in FY2021 to $418.8M in FY2025, achieving a 5-year revenue CAGR of 11.5% from FY2020 to FY2025. Annual revenue growth was 17.5% in FY2021, 17.3% in FY2022, 5.6% in FY2023, and 8.7% in both FY2024 and FY2025. Gross margin expanded to 61.5% in FY2025, up from 59.9% in FY2024. Operating margin recovered to 5.0% in FY2025 after dropping to -11.5% in FY2023 and -0.4% in FY2024. Net income improved from -$55.4M in FY2023 to -$1.6M in FY2025. In the latest quarter ended June 30, 2026, quarterly revenue grew 1.0% year-over-year, while quarterly earnings declined 14.1%.

As of June 30, 2026, Certara held $184.1M in cash and short-term investments against total debt of $291.8M, resulting in net debt of $107.7M. Total assets stood at $1.40B, and shareholders' equity was $966.5M. The company maintains a current ratio of 2.55 and a debt-to-equity ratio of 0.30. In FY2025, operating cash flow reached $96.3M, funding capital expenditures of $26.6M and share buybacks of $42.6M. Over 5 years, the share count changed by -0.8%.

At a last close of $9.37, Certara trades at an enterprise value of $1.43B and a forward P/E of 27.2x, which is above the 17.3x median of its US-listed Healthcare peers. Its EV to EBITDA multiple is 17.4x, compared to the peer median of 12.0x, while its price-to-sales of 3.4x is below the peer median of 4.1x. Over the past year, the stock returned -26.0%, trailing the S&P 500 (SPY) return of 16.8%. Over 5 years, CERT returned -75.2% compared to an 83.0% return for the benchmark.

Wall Street coverage consists of 4 Strong Buy ratings and 9 Hold ratings, with 0 Buy, Sell, or Strong Sell ratings. The mean price target is $9.17, representing a 2.2% discount to the last close of $9.37. For the fiscal year ending December 31, 2026, analysts estimate revenue of $378.6M and EPS of $0.34, representing an estimated EPS decline of 22.7%. Certara beat EPS estimates in 1 of the last 4 quarters. The next earnings date is November 5, 2026.

This page is an AI-written research summary of Certara, Inc. (CERT). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CERT income statement, CERT balance sheet, CERT key metrics, CERT analyst forecast, CERT chart. See the CERT stock overview for the latest quote and news.